Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
EBITDA Margin
-280.10%
TTM · Period ending:
LCTX EBITDA Margin
Latest reported-280.10%period ending
Latest reported-280.10%period ending
LCTX EBITDA Margin (-1300.00% → -280.10%)
Annual ebitda margin
High-resolution chart · PNG
LCTX ebitda margin history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Margin |
|---|---|
| -466.8041% | |
| -189.2094% | |
| -252.5433% | |
| -170.6114% | |
| -1,088.2187% | |
| -3,157.5679% | |
| -2,427.3342% | |
| -2,663.9831% | |
| -2,084.8214% | |
| -2,407.1936% | |
| -2,347.0797% | |
| -2,171.7842% | |
| -1,208.4556% | |
| -1,309.4483% | |
| -374.8054% | |
| -242.4628% | |
| -181.0582% | |
| -186.0874% | |
| -118.4661% | |
| -150.7609% | |
| -220.2056% | |
| -268.8965% | |
| -158.0175% | |
| -394.7814% | |
| -2,105.7472% | |
| -9,553.4977% | |
| -549.4141% | |
| -800% | |
| -3,650% | |
| -3,200% | |
| -2,000% | |
| -2,500% | |
| -1,600% | |
| -1,300% |